Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan with and without Filgrastim in Healthy Adults
NCT02703051Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of uproleselan in acute myeloid leukemia (AML) (3 arms), sponsored by GlycoMimetics. Primary endpoint: Measurement of subsets of WBC at 10 days. Started Nov 2015; status: completed.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02703051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703051.